Download - Glenmark

More documents

Recommendations

Info

Schedules annexed to and forming part of the Financial Statements (All amounts in millions of Indian Rupees, unless otherwise stated) 16. Extracts of Assets and Liabilities as on 31 March 2011 and Income and Expenses for the year ended 31 March 2011 related to the interest of the Company (without elimination of the effect of transactions between the Company and <strong>Glenmark</strong> Pharmaceuticals (Thailand) Co. Ltd., Thailand) have been extracted from the audited accounts: Particulars 2010-2011 2009-2010 Assets Net fixed assets including capital work-in-progress - - Deferred Tax Asset 0.38 0.24 Cash Bank Balances 0.14 1.03 Loans and Advances - 0.06 Liabilities Current Liabilities 0.02 0.14 Income Net Sales - - Expenses Selling and Operating Expenses 0.86 1.27 Depreciation - - Provision for Taxation including Deferred tax (0.13) (0.19) 17. VALUE OF IMPORTS ON CIF BASIS Capital Goods 166.85 77.92 Materials 158.84 150.44 325.69 228.36 18. EARNINGS IN FOREIGN CURRENCY Export of goods calculated on FOB basis 3,020.01 2,649.15 Guarantee Commission 11.21 26.06 Interest on loan to subsidiaries 308.04 278.25 3,339.26 2,953.46 19. EXPENDITURE IN FOREIGN CURRENCY Travelling expenses 42.60 45.56 Professional and Consultancy charges 7.00 36.94 Export promotional expenses and export commission 176.10 132.00 Salary and related expenses 95.81 99.65 Product registration expenses 38.03 47.58 Interest expenses 264.09 12.88 QIB issue expenses 10.64 65.83 FCCB premium on redemption 600.03 94.76 Others 324.56 222.22 1,558.86 757.42 20. DIVIDEND REMITTANCE IN FOREIGN CURRENCY Number of non-resident shareholders 16 22 Number of Equity Shares held by them 217,610 163,240 Amount of dividend paid (gross), TDS ` Nil (2010 - ` Nil) 0.09 0.07 Year to which dividend relates 2009-2010 2008-2009 21. PRIOR YEAR COMPARATIVES The financial statements of the Company for the immediately preceding year were audited and reported by another firm of Chartered Accountants. Prior year’s figures have been regrouped or reclassified wherever necessary to confirm to current year’s classification. 76 GLENMARK PHARMACEUTICALS LIMITED
Additional information as required under Part IV of Schedule VI to the Companies Act, 1956. Balance Sheet Abstract & Company’s General Business Profile (a) (b) (c) (d) (e) (` in Thousands) Registration Details Registration No. 1 9 9 8 2 State Code 1 1 Date Month Year Balance Sheet Date 3 1 0 3 2 0 1 1 Capital raised during the year Public Issue Rights Issue N I L N I L Bonus Issue Qualified Institutions Placement Issue N I L N I L Preferential offer of shares under Employee stock option scheme Conversion of FCC Bond 4 3 4 . 5 0 N I L Position of mobilisation and deployment of funds Total Liabilities including Shareholders’ Funds Total Assets 3 3 8 4 3 3 4 6 3 3 8 4 3 3 4 6 SOURCES OF FUNDS Paid-up Capital Reserves and Surplus 2 7 0 2 7 2 1 9 5 2 7 1 3 8 Secured Loans Unsecured Loans 1 6 0 1 3 2 0 9 8 6 1 1 4 2 Deferred Tax Liability 3 3 0 5 7 0 APPLICATION OF FUNDS Net Fixed Assets Investments 2 6 3 7 2 2 0 1 0 4 1 2 4 7 0 Net Current Assets Deferred Tax Assets 1 8 4 3 9 4 8 4 1 0 1 2 6 8 Accumulated Losses Miscellaneous Expenditure N I L N I L Performance of the Company Turnover (Total Income) Total Expenditure 1 1 8 5 0 2 3 8 9 3 4 2 1 3 6 Profit/(Loss) Before Tax Profit/(Loss) After Tax 2 5 0 8 1 0 2 2 1 2 1 7 8 8 Basic Earnings per Share in ` Diluted Earnings per Share in ` 7 . 8 6 7 . 8 5 Dividend Rate % 4 0 Generic Names of Three Principal Products of Company Item Code No. (ITC code) Product Description 3 0 0 4 8 0 . 0 0 Terbutaline Sulphate + Bromehexine Hydrochloride + Guaiphenesin 3 0 0 4 9 0 . 9 9 Clotrimazole 3 0 0 4 9 0 . 7 9 Telmisartan Annual Report 2010-2011 77
Page 35 and 36: Profiles of Directors Mr. Gracias S
Page 37 and 38: DIRECTORS Mr. D. R. Mehta, Mrs. B.
Page 39 and 40: 3. Metformin ER Tablets 1000 mg 4.
Page 41 and 42: ANNEXURE - B Disc losure in the Dir
Page 43 and 44: Report on Corporate Governance Purs
Page 45 and 46: 5. Shareholders’/Investors’ Gri
Page 47 and 48: Distribution Schedule as on 31 Marc
Page 49 and 50: Market Price Data: High, low during
Page 51 and 52: Certification by the Chief Executiv
Page 53 and 54: Auditors’ Report To, The Members
Page 55 and 56: (b) The dues outstanding in respect
Page 57 and 58: Profit and Loss Account (All amount
Page 59 and 60: Cash Flow Statement (All amounts in
Page 61 and 62: Schedules annexed to and forming pa
Page 79: Schedules annexed to and forming pa
Page 83 and 84: Consolidated Statement of Financial
Page 85 and 86: Consolidated Statement of Comprehen
Page 87 and 88: Notes to Consolidated Financial Sta
Page 89 and 90: the foreign entity and translated i
Page 91 and 92: The Group’s internal drug develop
Page 93 and 94: Financial liabilities are recognise
Page 95 and 96: In those cases where the possible o
Page 97 and 98: NOTE B - BASIS OF CONSOLIDATION The
Page 99 and 100: NOTE H - PROPERTY, PLANT AND EQUIPM
Page 101 and 102: Working Capital Facilities is secur
Page 103 and 104: NOTE R - MATERIALS CONSUMED Materia
Page 105 and 106: Net compensated absence cost for th
Page 107 and 108: NOTE Y - SEGMENT REPORTING The Chie
Page 109 and 110: The Group’s trade and other recei
Page 111 and 112: As at 31 March 2011, the Group’s
Page 113 and 114: Depreciation Further, depreciation
Page 116 and 117: GLENMARK PHARMACEUTICALS LIMITED Re
Page 118: GLENMARK PHARMACEUTICALS LIMITED Re

Download - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?